FDA Approved: VYVANSE — Original Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved Vyvanse (lisdexamfetamine dimesylate) from Takeda as the original NDA (NDA021977) for the treatment of attention-deficit/hyperactivity disorder. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Vyvanse (lisdexamfetamine dimesylate)

Snippet

ORIG AP for VYVANSE (LISDEXAMFETAMINE DIMESYLATE)